Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385687 | 0.82 | KMT2A (0.53) | KDM4EKMT2ACHRM5CHKANAPRT | |
| SCHEMBL429504 | 0.80 | KDM4E (0.52) | KDM4EKMT2ACHRM5CHKANAPRT | |
| Bicarbonate SCHEMBL9762926 | 0.79 | CHRM5 (0.76) | KDM4EKMT2ACHRM5CHKANAPRT | |
| SCHEMBL29123175 | 0.78 | KDM4E (0.82) | KDM4EKMT2ACHRM5CHKANAPRT | |
| SCHEMBL455438 | 0.78 | KMT2A (0.53) | KDM4EKMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL27928038 | 0.78 | MAPT (0.50) | KDM4EKMT2ACHRM5CHKAPOLQ | |
| Bicarbonate SCHEMBL28267252 | 0.77 | CHRM5 (0.73) | KDM4EKMT2ACHRM5CHKANAPRT | |
| Acetic Acid SCHEMBL7780301 | 0.77 | CHRM5 (0.73) | KDM4EKMT2ACHRM5CHKANAPRT | |
| Bicarbonate SCHEMBL28588179 | 0.77 | CHRM5 (0.73) | KDM4EKMT2ACHRM5CHKANAPRT | |
| SCHEMBL14192258 | 0.77 | KMT2A (0.49) | KDM4EKMT2ACHRM5CHKAMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2019214399-A1 | BENZO- SEVEN-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | 罗欣药业(上海)有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| CN-109053742-A | New tricyclic compound | ABBVIE 公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108774237-A | New tricyclic compound | ABBVIE 公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104370909-B | Tricyclic compound | ABBVIE 公司 | 2018-09-11 | — | — | CN | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| CN-101128473-A | Adenosine derivatives having a2a receptor activity | NOVARTIS AG (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-4426523-A | Preparation of 1-amino-1,3,5-triazine-2,4(1H, 3H)-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | KDM4E 2244/4885KMT2A 762/4885CHRM5 4294/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | KDM4E 4131/4885KMT2A 3881/4885CHRM5 4065/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | KDM4E 4131/4885KMT2A 3881/4885CHRM5 4065/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | KDM4E 2113/4885KMT2A 703/4885CHRM5 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.